Arrowhead Research (ARWR) PT Lowered to $5 at Jefferies Following Clinical Hold
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies analyst Eun Yang reiterated a Hold rating and cut his price target on Arrowhead Research (NASDAQ: ARWR) to $5.00 (from $6.50) following clinical hold.
Yang commented, "FDA's decision to place a clinical hold on Heparc-2004 trial of ARC-520 based on death in non-human primate study came as a surprise. While ARWR does not expect the hold to delay progress of any of its programs, until proven it's safe, we take a cautious view, adjusting PT to $5 from $6.50."
Shares of Arrowhead Research closed at $4.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades PennTex Midstream Partners, LP (PTXP) to Hold
- UPDATE: Stifel Upgrades Martin Midstream Partners (MMLP) to Buy
- Mizuho Securities Raises Price Target on Noble Midstream Partners LP (NBLX) to $37
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!